Literature DB >> 33826209

The Effect of the Cardiac Myosin Activator, Omecamtiv Mecarbil, on Right Ventricular Structure and Function in Chronic Systolic Heart Failure (COSMIC -HF).

Tor Biering Sørensen1,2,3, Masatoshi Minamisawa1,4, Jiankang Liu1, Brian Claggett1, Alexander I Papolos5, G Michael Felker6, John J V McMurray7, Jason C Legg8, Fady I Malik9, Narimon Honarpour8, Christopher E Kurtz8, John R Teerlink10, Scott D Solomon1.   

Abstract

Entities:  

Year:  2021        PMID： 33826209     DOI： 10.1002/ejhf.2181

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN： 1388-9842            Impact factor:   15.534


× No keyword cloud information.
  4 in total

Review 1.  Targeting the sarcomere in inherited cardiomyopathies.

Authors:  Sarah J Lehman; Claudia Crocini; Leslie A Leinwand
Journal:  Nat Rev Cardiol       Date:  2022-03-18       Impact factor: 49.421

Review 2.  Myosin modulators: emerging approaches for the treatment of cardiomyopathies and heart failure.

Authors:  Sharlene M Day; Jil C Tardiff; E Michael Ostap
Journal:  J Clin Invest       Date:  2022-03-01       Impact factor: 14.808

Review 3.  Application of optical tweezers in cardiovascular research: More than just a measuring tool.

Authors:  Yi Yang; Zhenhai Fu; Wei Zhu; Huizhu Hu; Jian'an Wang
Journal:  Front Bioeng Biotechnol       Date:  2022-09-06

Review 4.  Cardiac Myosin Activation in the Treatment of Congestive Heart Failure: New Therapeutic Options and Review of Literature.

Authors:  Arroj Ali; Ramy Abdelmaseih; Ravi Thakker; Mohammed Faluk; Syed Mustajab Hasan
Journal:  Heart Views       Date:  2022-02-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.